SCHEMBL12059796

SCHEMBL12059796

O=C(O)c1ccc(C(=O)Nc2cccc3cc[nH]c23)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.51
NPC1 O15118 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RAB9A P51151 1/20 0.49
PARP1 P09874 6/20 0.48
PTPRC P08575 1/20 0.47
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
PTPRB P23467 1/20 0.47
PTPRE P23469 1/20 0.47
PTPN6 P29350 1/20 0.47
NR3C1 P04150 1/20 0.47
PGR P06401 1/20 0.47
NR3C2 P08235 1/20 0.47
AR P10275 1/20 0.47
ATR Q13535 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27698981 0.81 KEAP1 (0.56) KEAP1NPC1RAB9APTPRCPTPN2
SCHEMBL12044324 0.80 RAB9A (0.48) NPC1RAB9APARP1NR3C1PGR
SCHEMBL4467330 0.79 DHODH (0.58) NPC1RAB9ADHPSTRPV1NR1H4
SCHEMBL3061760 0.78 NR3C1 (0.56) KEAP1CYP2C9CYP2C19PTPN1NR3C1
SCHEMBL31456523 0.76 NR3C1 (0.57) KEAP1NR3C1PGRNR3C2AR
SCHEMBL6091339 0.76 NR3C1 (0.57) KEAP1NR3C1PGRNR3C2AR
SCHEMBL30026274 0.76 PDPK1 (0.57) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL5497010 0.76 PDPK1 (0.57) KEAP1PTPRCPTPN2PTPN1PTPRB
SCHEMBL12044296 0.76 GRIN2D (0.55) NPC1RAB9AMEN1KMT2AHSD17B10
SCHEMBL3659724 0.75 RAB9A (0.84) NPC1CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319416-A1 Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2011-12-29 US disclosed
WO-2010088408-A2 SUBUNIT SELECTIVE NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS EMORY UNIVERSITY (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319416-A1 Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions GRIN1, GRIN2A, GRIN2B KEAP1 2601/4885NPC1 875/4885CYP1A2 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.